Dermapharm (DMP) Q4 2024 earnings summary

Executive summary

• Achieved FY 2024 revenue of €1,180.8m, up 4.0% year-over-year, meeting guidance.

• Adjusted EBITDA reached €315.6m, exceeding the upper end of guidance and up 1.7% year-over-year.

• Net income (EAT) rose 84.6% to €111.7m, driven by organic growth and improved financial result.

• Proposed dividend of €0.90 per share for FY 2024.

Financial highlights

• Revenue growth supported by strong branded pharmaceuticals, offsetting declines in Arkopharma and vaccine business.

• Adjusted EBITDA margin at 26.7%; margin excluding vaccine business improved by 1.4 percentage points.

• Earnings before tax (EBT) increased 62.3% to €172.0m, with EBT margin at 14.6%.

• Free cash flow of €171.8m, reversing a negative FCF in the prior year.

• Net debt reduced by €67m during 2024, with net debt/adjusted EBITDA at 2.8.

Outlook and guidance

• FY 2025 revenue expected between €1,160m and €1,200m, reflecting a slight decrease or stable development.

• Adjusted EBITDA guidance for 2025 set at €322m–332m, indicating further margin improvement.

• Focus on organic growth in branded pharmaceuticals, new launches, and international expansion.

• Anticipates lower parallel import revenues and profits due to portfolio focus.

• Outlook reflects healthcare sector austerity and stricter drug approval requirements.